We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Activity of sunitinib in patients with advanced neuroendocrine tumors.
- Authors
Kulke, Matthew H; Lenz, Heinz-Josef; Meropol, Neal J; Posey, James; Ryan, David P; Picus, Joel; Bergsland, Emily; Stuart, Keith; Tye, Lesley; Huang, Xin; Li, Jim Z; Baum, Charles M; Fuchs, Charles S
- Abstract
Standard cytotoxic chemotherapy has limited efficacy in metastatic neuroendocrine tumor patients. Neuroendocrine tumors express vascular endothelial growth factor (VEGF) and its receptor (VEGFR). Sunitinib malate, an oral tyrosine kinase inhibitor, has activity against VEGFRs as well as platelet-derived growth factor receptors, stem-cell factor receptor, glial cell line-derived neurotrophic factor, and FMS-like tyrosine kinase-3. We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 20, p3403
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.15.9020